14 Jan. 2026

Enimmune’s Enterovirus Vaccine Obtains Vietnam GMP Certification

Enimmune Corp. (TPEx: 6564), an Adimmune Corporation’s subsidiary, announced yesterday through a material information disclosure that it has obtained Vietnam GMP certification for its Enterovirus 71 (EV71) vaccine, EnVAX-A71, which is manufactured at Adimmune’s Tanzi Cell Culture Plant. The certification has been officially published on the website of the Drug Administration of Vietnam (DAV) and Adimmune (TWSE: 4142) is included in the list of GMP-compliant foreign manufacturing facilities.

19 Dec. 2025

Adimmune Celebrates 60th Anniversary with Community-Focused Charity Event

Adimmune Corporation (TWSE: 4142) marked its 60th anniversary yesterday with a charity Christmas fair held in Tanzi District, Taichung, reaffirming the Company’s long-standing commitment to community engagement, public health, and sustainable development.

17 Dec. 2025

Adimmune and Enimmune Receive Gold Award for Corporate Epidemic Prevention; Recognized Among Top 10 Vaccine News of 2025

Adimmune Corporation (TWSE: 4142) today announced that both Adimmune and its subsidiary, Enimmune Corp. (TWSE: 6564), have been honored with the Gold Award for Corporate Epidemic Prevention, and recognized among the Top 10 Vaccine News of 2025.

21 Oct. 2025

Adimmune Group Vaccines Listed in WHO Full Vaccine Product List

Adimmune Corporation (TWSE:4142) today announced that three of its vaccines—the seasonal influenza vaccine, tetanus toxoid vaccine, and the enterovirus 71 (EV71) vaccine developed by its subsidiary Enimmune—are now officially listed in the World Health Organization (WHO) Full Vaccine Product List published in September. Inclusion in the WHO list signifies that Adimmune has entered the global public health supply chain, marking a significant milestone for Taiwan’s vaccine industry as its quality and manufacturing capabilities gain recognition from the global health community.

30 Sep. 2025

Adimmune and Enimmune Rush 5,000 Doses of Tetanus Vaccine to Hualien Disaster Zone

Adimmune Corporation (4142) announced today that, in coordination with the Taiwan Centers for Disease Control (CDC) and the Hualien County Health Bureau, it has urgently delivered 5,000 doses of tetanus vaccine to Guangfu Township in Hualien, where residents and volunteers are working intensively on post-disaster cleanup. The donation aims to protect both disaster victims and relief workers from tetanus infections caused by injuries sustained in debris-laden flood zones.

26 Aug. 2025

ANVISA’s GMP Certification Granted to Adimmune Significantly Advances the Progress toward Regulatory Approval in Brazil

Adimmune Corporation (4142) today announced that its Tanzi plant in Taichung has officially received Good Manufacturing Practice (GMP) certification from the Brazilian Health Regulatory Agency (ANVISA). The certification follows an on-site inspection conducted in June, during which ANVISA officials reviewed Adimmune’s influenza vaccine production process.

08 Aug. 2025

Adimmune Enhances Technical Capabilities and Expands CDMO Capacity

Adimmune Corporation (4142) announced today at its investor conference that the company has implemented operational adjustments in response to shifting global political and economic circumstances. In the first half of this year, Adimmune successfully passed inspections by Brazilian ANVISA and EMA respectively. To meet growing demand from clients for additional production capacity, the company’s existing facilities are operating at full load. Adimmune has therefore initiated the installation of a third automated aseptic filling line with an annual capacity of 4 million doses, designed to serve customized, small-batch, and high-value products, and provide end-to-end services from clinical trials to commercial manufacturing—enhancing both capacity and scheduling flexibility.

09 Jul. 2025

Adimmune Adopts QbD to Enhance Process and Product Development

Adimmune Corporation (TWSE: 4142) has been adopting Quality by Design (QbD) practices to align with international standards, enhance its capabilities in process and product development, support international CDMO (contract development and manufacturing organization) projects, and drive new business and technology expansion.

03 Jul. 2024

Enimmune's Enterovirus 71 Vaccine Demonstrates 99.21% Efficacy in Phase III Clinical Trial

Enimmune Corp. (TWSE: 6564), a subsidiary of Adimmune Corporation, today announced the unblinding results of its phase III clinical trial for EnVAX-A71, Enimmune’s enterovirus 71 (EV71) vaccine. The trial demonstrated an impressive vaccine efficacy of 99.21%, establishing EnVAX-A71 as the most effective EV71 vaccine currently available worldwide.

14 May. 2024

Adimmune Signs SMTA2 with WHO

Adimmune Corporation (TWSE: 4142) announced that, following years of negotiation, Adimmune and World Health Organization (WHO) have concluded the SMTA2 (Standard Material Transfer Agreement 2) under the Pandemic Influenza Preparedness (PIP) Framework. The SMTA2 ensures that, in the event of an influenza pandemic, the partner influenza vaccine manufacturers or pharmaceutical companies can access the virus strains from WHO to promptly develop the pandemic influenza vaccine or antiviral drugs in response. In exchange, Adimmune is obligated to donate and reserve a percentage of its newly developed pandemic influenza vaccines production for WHO to address the global pandemic and fulfill Adimmune’s commitments and obligations under the SMTA2.

26 Dec. 2023

Adimmune Broadens Market Reach for Flu Vaccine, Initiates New CDMO Ventures in 2024

Adimmune Corporation (TWSE: 4142) announced during the institutional investor conference today that Adimmune has submitted the application for marketing authorization of its quadrivalent influenza vaccine to Brazilian ANVISA in November, marking its official initiation for entry into the Southern Hemisphere’s influenza market. Another significant development is that Adimmune has successfully resumed production of its tetanus vaccine in Taiwan, and the supply has generated positive reception in the domestic market. The demand of tetanus vaccine is also strong in Southeast Asia and China, and Adimmune may anticipate a promising leap in export sales once the tetanus vaccine is approved in those markets. Building on its current CDMO performance, Adimmune foresees expanding partnership with bio-pharmaceutical manufacturers in Korea and France and expects to realize substantial growth in 2024.

24 Oct. 2023

Adimmune’s Tetanus Vaccine Set to Re-launce by Year’s End

Adimmune Corporation (TWSE: 4142) today announced that the Company has successfully extended the marketing authorization for its tetanus vaccine and is prepared to commence the steady supply of no less than one million doses annually for the domestic market in Taiwan as early as November 2023.